Systemic adverse events: abnormal cortisol; end of treatment (1‐6 weeks) · children and adults, most with moderate to severe eczema
1 finding from 1 review
Clinician‐reported signs of eczema: IGA (number with cleared or marked improvement); short term (earliest time point within 1‐4 weeks) · children and adults, most with moderate to severe eczema
Potent showed no clear difference in clinician‐reported signs of eczema: IGA (number with cleared or… compared with moderate‐potency topical corticosteroid (moderate certainty).
1 finding from 1 review
Functional ability in targeted activities: personal goals ‐ performance (participant self‐report) · people with mild‐to‐moderate dementia (at the end of therapy)
1 finding from 1 review
Functional ability · people with mild‐to‐moderate dementia (at medium‐term follow‐up)
1 finding from 1 review
Self‐efficacy · people with mild‐to‐moderate dementia (at medium‐term follow‐up)
1 finding from 1 review
Mood: depression (participant self‐report) · people with mild‐to‐moderate dementia (at medium‐term follow‐up)
1 finding from 1 review
QoL · people with mild‐to‐moderate dementia (at medium‐term follow‐up)
1 finding from 1 review
Quality of life: psychological (care partner self‐report) · people with mild‐to‐moderate dementia (at medium‐term follow‐up)
1 finding from 1 review
Functional ability in targeted activities: personal goals ‐ performance (informant report of participant) · people with mild‐to‐moderate dementia (at the end of therapy)
1 finding from 1 review
Functional ability · people with mild‐to‐moderate dementia (at the end of therapy)
1 finding from 1 review
Self‐efficacy · people with mild‐to‐moderate dementia (at the end of therapy)
1 finding from 1 review
Mood: depression (participant self‐report) · people with mild‐to‐moderate dementia (at the end of therapy)
1 finding from 1 review
QoL · people with mild‐to‐moderate dementia (at the end of therapy)
1 finding from 1 review
Quality of life: psychological (care partner self‐report) · people with mild‐to‐moderate dementia (at the end of therapy)
1 finding from 1 review
Functional ability in targeted activities: personal goals ‐ performance (participant self‐report) · people with mild‐to‐moderate dementia (at medium‐term follow‐up)
1 finding from 1 review
Functional ability in targeted activities: personal goals ‐ performance (informant report of participant) · people with mild‐to‐moderate dementia (at medium‐term follow‐up)
1 finding from 1 review
Interventions (corticosteroids included in all regimens)a · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
aprepitant + palonosetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
1 finding from 1 review
netupitant + palonosetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
1 finding from 1 review
rolapitant + granisetron · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy
1 finding from 1 review